3 Jul 2020 07:00
Diaceutics PLC
("Diaceutics" or the "Company")
Issue of Share Options
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces the issue of share options over ordinary shares of 0.2p each in the Company ("Share Options") on 30 June 2020, to certain members of the Company's senior management team and other key staff. These share options have been issued pursuant to certain contractual share-based entitlements in place prior to the IPO and are governed by the rules of the Company's Employee Share Option Plan ("ESOP").
Share Options were granted as follows:
Name | Number of Share Options granted | Total no. of ordinary shares under option post grant | % of existing issued share capital |
Damian Thornton (COO and PDMR) | 4,200 | 102,704 | 0.12% |
Jordan Clark (CTO and PDMR) | 4,200 | 76,114 | 0.09% |
Susanne Munksted (CPO and PDMR) | 4,200 | 70,672 | 0.08% |
A further 214,500 Share Options were granted to 51 employees, each of whom received 4,200 Share Options.
The Share Options vest in full after three years following date of grant. The exercise price of the Share Options is 0.2p per share being the nominal value of the share.
Following the grant the total number of share options outstanding granted to the Company's Directors, senior management team and key employees is 1,790,762, representing approximately 2.13% of the Company's current issued share capital of 84,068,923.
Enquiries:
Diaceutics PLC | www.diaceutics.com | ||
Peter Keeling, Chief Executive Officer | via Walbrook PR | ||
Philip White, Chief Financial Officer |
| ||
|
| ||
Cenkos Securities plc (Nominated adviser and broker) | +44 (0)207 397 8900 | ||
Callum Davidson / Giles Balleny |
| ||
Michael Johnson (Sales) |
| ||
|
| ||
Walbrook PR | Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com | ||
Anna Dunphy | Mob: +44 (0)7876 741 001 | ||
Paul McManus | Mob: +44 (0)7980 541 893 | ||
|
|
|
|
About Diaceutics
At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world's first Diagnostic Network solution for the development and commercialisation of precision medicine diagnostics. The Company has worked on every precision medicine brought to market and provides services to 36 of the world's leading pharmaceutical companies. We have built the world's largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Damian Thornton | |||||
2 | Reason for notification |
| |||||
a. | Position/Status | Chief Operating Officer | |||||
b. | Initial notification/ Amendment | Initial | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | Diaceutics PLC | |||||
b. | LEI | 213800VEWQBB39ZB8J81 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Options over new ordinary shares of 0.2p each
ISIN: GB00BJQTGV64 | |||||
b. | Nature of the transaction | Grant of share options | |||||
c. | Price(s) and volume(s) |
|
|
|
|
| |
| Price(s) | Volume(s) |
| ||||
Exercise price of 0.2p per share | 4,200 |
| |||||
| |||||||
e. | Date of the transaction | 30 June 2020 | |||||
f. | Place of the transaction | Outside a trading venue | |||||
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Jordan Clark | |||||
2 | Reason for notification |
| |||||
a. | Position/Status | Chief Technology Officer | |||||
b. | Initial notification/ Amendment | Initial | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | Diaceutics PLC | |||||
b. | LEI | 213800VEWQBB39ZB8J81 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Options over new ordinary shares of 0.2p each
ISIN: GB00BJQTGV64 | |||||
b. | Nature of the transaction | Grant of share options | |||||
c. | Price(s) and volume(s) |
|
|
|
|
| |
| Price(s) | Volume(s) |
| ||||
Exercise price of 0.2p per share | 4,200 |
| |||||
| |||||||
e. | Date of the transaction | 30 June 2020 | |||||
f. | Place of the transaction | Outside a trading venue | |||||
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Susanne Munksted | |||||
2 | Reason for notification |
| |||||
a. | Position/Status | Chief Precision Officer | |||||
b. | Initial notification/ Amendment | Initial | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | Diaceutics PLC | |||||
b. | LEI | 213800VEWQBB39ZB8J81 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Options over new ordinary shares of 0.2p each
ISIN: GB00BJQTGV64 | |||||
b. | Nature of the transaction | Grant of share options | |||||
c. | Price(s) and volume(s) |
|
|
|
|
| |
| Price(s) | Volume(s) |
| ||||
Exercise price of 0.2p per share | 4,200 |
| |||||
| |||||||
e. | Date of the transaction | 30 June 2020 | |||||
f. | Place of the transaction | Outside a trading venue | |||||
Diaceutics (DXRX)